Algorae PharmaceuticalsASX:1AI -9.09% EV-to-FCF is -26.14 as of Jun. 25, 2026. The stock has 2 warning signs investors should review. Among 328 Biotechnology companies, Algorae Pharmaceuticals ranks worse than 304877.74% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Algorae Pharmaceuticals's Enterprise Value is A$18.37 Mil.
Algorae Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.70 Mil. Therefore, Algorae Pharmaceuticals's EV-to-FCF for today is -26.14.
The historical rank and industry rank for Algorae Pharmaceuticals's EV-to-FCF or its related term are showing as below:
ASX:1AI'
s EV-to-FCF Range Over the Past 10 Years
Min: -29.02 Med: -0.23 Max: 0.84
Current: -29.02
During the past 13 years, the highest EV-to-FCF of Algorae Pharmaceuticals was 0.84. The lowest was -29.02. And the median was -0.23.
ASX:1AI's EV-to-FCF is ranked worse than 100% of 328
companies
in the Biotechnology industry
Industry Median: 14.86
vs ASX:1AI: -29.02
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Algorae Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Algorae Pharmaceuticals's share price for today is A$0.01.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Algorae Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.001.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Algorae Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Algorae Pharmaceuticals EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Algorae Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Algorae Pharmaceuticals's EV-to-FCF falls into.
Algorae Pharmaceuticals's current Enterprise Value is A$18.37 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Algorae Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.70 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Algorae Pharmaceuticals (ASX:1AI) has a EV-to-FCF of -26.14 as of Jun. 25, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Algorae Pharmaceuticals and its competitors. According to the industry distribution chart, Algorae Pharmaceuticals ranks #999999 out of 328 companies in the Biotechnology industry.
Is Algorae Pharmaceuticals' EV-to-FCF too high?
Algorae Pharmaceuticals' current EV-to-FCF is -26.14. Based on the distribution chart, Algorae Pharmaceuticals ranks #999999 out of 328 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Algorae Pharmaceuticals' EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Algorae Pharmaceuticals ranks #999999 out of 328 companies for EV-to-FCF. This places Algorae Pharmaceuticals in the lower half of its industry. The industry median EV-to-FCF is 14.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.86, based on 328 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Algorae Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Algorae Pharmaceuticals's current EV-to-FCF is -26.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Algorae Pharmaceuticals stock overvalued right now?
Algorae Pharmaceuticals (ASX:1AI) has a current EV-to-FCF of -26.14. The current EV-to-FCF is -26.14. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Algorae Pharmaceuticals (ASX:1AI), the current EV-to-FCF is -26.14 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer's disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:1AI has been successfully added to your 